Gritstone bio Investor Relations Material

Gritstone bio, Inc. is a clinical-stage biotechnology company engaged in developing immunotherapies against multiple cancer types and infectious diseases. It offers, among others, SYSTIMAX, an intravenous immunotherapy for the treatment of patients with acute myeloid leukemia (AML), and other related blood cancers, and SYSTIMAX-ID, an intravenous immunotherapy for the treatment of patients with infectious diseases. Its immunotherapies include fully human monoclonal antibodies that target specific antigens associated with the surfaces of cells that drive malignancies or infection.